Publisher Correction: Toripalimab or placebo plus chemotherapy as first-line treatment in advanced nasopharyngeal carcinoma: a multicenter randomized phase 3 trial

Nature Medicine ◽

10.1038/s41591-021-01673-3 ◽

2022 ◽

Author(s):

Hai-Qiang Mai ◽

Qiu-Yan Chen ◽

Dongping Chen ◽

Chaosu Hu ◽

Kunyu Yang ◽

...

Keyword(s):

Nasopharyngeal Carcinoma ◽

Line Treatment ◽

Phase 3 ◽

First Line Treatment

Download Full-text

JUPITOR-02: Randomized, Double-Blind, Phase 3 Study of Toripalimab or Placebo Plus Cisplatin and Gemcitabine as First-Line Treatment for Recurrent or Metastatic Nasopharyngeal Carcinoma

SSRN Electronic Journal ◽

10.2139/ssrn.3826212 ◽

2021 ◽

Author(s):

Hai-Qiang Mai ◽

Qiu-Yan Chen ◽

Dongping Chen ◽

Chaosu Hu ◽

Kunyu Yang ◽

...

Keyword(s):

Nasopharyngeal Carcinoma ◽

Line Treatment ◽

Phase 3 ◽

Double Blind ◽

Metastatic Nasopharyngeal Carcinoma ◽

First Line Treatment

Download Full-text

Toripalimab or placebo plus chemotherapy as first-line treatment in advanced nasopharyngeal carcinoma: a multicenter randomized phase 3 trial

Nature Medicine ◽

10.1038/s41591-021-01444-0 ◽

2021 ◽

Author(s):

Hai-Qiang Mai ◽

Qiu-Yan Chen ◽

Dongping Chen ◽

Chaosu Hu ◽

Kunyu Yang ◽

...

Keyword(s):

Nasopharyngeal Carcinoma ◽

Line Treatment ◽

Phase 3 ◽

First Line Treatment

Download Full-text

Camrelizumab versus placebo in combination with gemcitabine and cisplatin as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma (CAPTAIN-1st): a multicentre, randomised, double-blind, phase 3 trial

The Lancet Oncology ◽

10.1016/s1470-2045(21)00302-8 ◽

2021 ◽

Author(s):

Yunpeng Yang ◽

Song Qu ◽

Jingao Li ◽

Chaosu Hu ◽

Mingjun Xu ◽

...

Keyword(s):

Nasopharyngeal Carcinoma ◽

Line Treatment ◽

Phase 3 ◽

Double Blind ◽

Metastatic Nasopharyngeal Carcinoma ◽

First Line Treatment ◽

Gemcitabine And Cisplatin

Download Full-text

Faculty Opinions recommendation of Toripalimab or placebo plus chemotherapy as first-line treatment in advanced nasopharyngeal carcinoma: a multicenter randomized phase 3 trial.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.740583480.793588752 ◽

2021 ◽

Author(s):

Melvin Chua

Keyword(s):

Nasopharyngeal Carcinoma ◽

Line Treatment ◽

Phase 3 ◽

First Line Treatment

Download Full-text

Faculty of 1000 evaluation for Bevacizumab plus paclitaxel versus bevacizumab plus capecitabine as first-line treatment for HER2-negative metastatic breast cancer: interim efficacy results of the randomised, open-label, non-inferiority, phase 3 TURANDOT trial.

F1000 - Post-publication peer review of the biomedical literature ◽

10.3410/f.717976445.793471388 ◽

2013 ◽

Author(s):

Ana Maria Gonzalez-Angulo

Keyword(s):

Breast Cancer ◽

Metastatic Breast Cancer ◽

Metastatic Breast ◽

Line Treatment ◽

Phase 3 ◽

First Line Treatment

Download Full-text

Faculty Opinions recommendation of Adoptive T-cell transfer and chemotherapy in the first-line treatment of metastatic and/or locally recurrent nasopharyngeal carcinoma.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.718227384.793517241 ◽

2016 ◽

Author(s):

Bruce Brockstein

Keyword(s):

T Cell ◽

Nasopharyngeal Carcinoma ◽

Cell Transfer ◽

Line Treatment ◽

Adoptive T Cell Transfer ◽

Recurrent Nasopharyngeal Carcinoma ◽

Locally Recurrent ◽

T Cell Transfer ◽

First Line Treatment

Download Full-text

First Line Treatment with Erlotinib Plus Bevacizumab or with Erlotinib Alone in Patients with Advanced Non-Squamous Non-Small-Cell Lung Cancer Harboring EGFR Mutations (NEJ026): An Open-Label, Randomized, Multicenter, Phase 3 Study

SSRN Electronic Journal ◽

10.2139/ssrn.3271416 ◽

2018 ◽

Author(s):

Haruhiro Saito ◽

Tatsuro Fukuhara ◽

Naoki Furuya ◽

Kana Watanabe ◽

Shunichi Sugawara ◽

...

Keyword(s):

Lung Cancer ◽

Egfr Mutations ◽

Line Treatment ◽

Small Cell Lung ◽

Phase 3 ◽

Multicenter Phase ◽

First Line Treatment

Download Full-text

Intermittent versus continuous oxaliplatin and fluoropyrimidine combination chemotherapy for first-line treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial

The Lancet Oncology ◽

10.1016/s1470-2045(11)70102-4 ◽

2011 ◽

Vol 12 (7) ◽

pp. 642-653 ◽

Author(s):

Richard A Adams ◽

Angela M Meade ◽

Matthew T Seymour ◽

Richard H Wilson ◽

Ayman Madi ◽

...

Keyword(s):

Colorectal Cancer ◽

Combination Chemotherapy ◽

Advanced Colorectal Cancer ◽

Line Treatment ◽

Phase 3 ◽

First Line Treatment

Download Full-text

Lenvatinib versus sorafenib for first-line treatment of unresectable hepatocellular carcinoma: patient-reported outcomes from a randomised, open-label, non-inferiority, phase 3 trial

The Lancet Gastroenterology & Hepatology ◽

10.1016/s2468-1253(21)00110-2 ◽

2021 ◽

Author(s):

Arndt Vogel ◽

Shukui Qin ◽

Masatoshi Kudo ◽

Yun Su ◽

Stacie Hudgens ◽

...

Keyword(s):

Hepatocellular Carcinoma ◽

Patient Reported Outcomes ◽

Line Treatment ◽

Phase 3 ◽

Unresectable Hepatocellular Carcinoma ◽

Carcinoma Patient ◽

Patient Reported ◽

First Line Treatment

Download Full-text

Efficacy and safety of tislelizumab, an anti-PD-1 antibody, versus sorafenib as first-line treatment in patients with advanced hepatocellular carcinoma in a phase 3, randomized, open-label, multicenter study - Trial in progress

Annals of Oncology ◽

10.1093/annonc/mdy151.181 ◽

2018 ◽

Vol 29 ◽

pp. v51

Author(s):

S. Qin ◽

R. Finn ◽

M. Kudo ◽

T. Meyer ◽

A. Vogel ◽

...

Keyword(s):

Hepatocellular Carcinoma ◽

Multicenter Study ◽

Study Trial ◽

Advanced Hepatocellular Carcinoma ◽

Line Treatment ◽

Efficacy And Safety ◽

Phase 3 ◽

First Line Treatment

Download Full-text